Clinical trial
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
NCT00086658 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00086658 |
|---|---|
| Title | Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) |
| Official title | A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypereosinophilia, Hypereosinophilic Syndrome |
| Intervention type | Drug |
| Interventions | mepolizumab |
| Enrollment | 86 |
| Start date | Mar 23, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Jul 9, 2004 |
| Last update posted | May 5, 2020 |
| Countries | Australia, Belgium, Canada, France, Germany, Italy, Switzerland, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: